Cargando…
Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety
BACKGROUND: Fragile X Syndrome (FXS) occurs as a result of a silenced fragile X mental retardation 1 gene (FMR1) and subsequent loss of fragile X mental retardation protein (FMRP) expression. Loss of FMRP alters excitatory/inhibitory signaling balance, leading to increased neuronal hyperexcitability...
Autores principales: | Schaefer, Tori L., Davenport, Matthew H., Grainger, Lindsay M., Robinson, Chandler K., Earnheart, Anthony T., Stegman, Melinda S., Lang, Anna L., Ashworth, Amy A., Molinaro, Gemma, Huber, Kimberly M., Erickson, Craig A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467053/ https://www.ncbi.nlm.nih.gov/pubmed/28616095 http://dx.doi.org/10.1186/s11689-017-9184-y |
Ejemplares similares
-
Emerging pharmacologic treatment options for fragile X syndrome
por: Schaefer, Tori L, et al.
Publicado: (2015) -
GABA(A) Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome
por: Schaefer, Tori L., et al.
Publicado: (2021) -
Role of acamprosate in sensorineural tinnitus
por: Sharma, Dinesh Kumar, et al.
Publicado: (2012) -
Unusual side effects with acamprosate
por: Sidana, Ajeet Kumar, et al.
Publicado: (2007) -
Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence
por: Yahn, Stephanie L., et al.
Publicado: (2013)